Detalles de la búsqueda
1.
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med
; 370(17): 1594-603, 2014 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-24720703
2.
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
N Engl J Med
; 370(21): 1973-82, 2014 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-24725237
3.
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
N Engl J Med
; 370(3): 222-32, 2014 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-24428468
4.
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med
; 370(17): 1604-14, 2014 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-24720679
5.
Exploratory study of oral combination antiviral therapy for hepatitis C.
N Engl J Med
; 368(1): 45-53, 2013 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23281975
6.
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
J Hepatol
; 63(4): 805-12, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26070406
7.
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Gastroenterology
; 147(2): 359-365.e1, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24818763
8.
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
J Hepatol
; 59(1): 18-23, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23439262
9.
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Proc Natl Acad Sci U S A
; 105(10): 3879-84, 2008 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-18332425
10.
Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.
HIV Clin Trials
; 10(2): 94-103, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19487179
11.
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
N Engl J Med
; 346(26): 2039-46, 2002 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-12087139
12.
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
HIV Clin Trials
; 8(4): 193-204, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17720659
13.
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
J Virol Methods
; 214: 29-32, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25528998
14.
HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.
Antivir Ther
; 20(2): 177-83, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-24941124
15.
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Antivir Ther
; 7(3): 165-74, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12487383
16.
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
Pediatr Infect Dis J
; 22(3): 216-24, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12634581
17.
Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.
J Clin Pharmacol
; 52(8): 1248-54, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21719718
18.
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
AIDS Res Hum Retroviruses
; 26(8): 841-5, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20672994
19.
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
J Acquir Immune Defic Syndr
; 54(2): 143-51, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20134330
20.
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
J Acquir Immune Defic Syndr
; 51(5): 554-61, 2009 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19512937